Plant Name: Cassia dentata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TDP1; PIK3CA; PIK3CB; PKM; GFER; NQO2; USP2; | |
| CA2; CA1; CA12; CA9; CA13; CA5B; CA5A; CA7; CA3; CA14; CA4; CA6; | |
| ESR1; | |
| PTGS1; MAOA; PTGS2; | |
| HIF1A; TP53; | |
| SLC6A2; SLCO1B3; SLCO1B1; | |
| HTT; LMNA; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.991E-11 | 9.881E-08 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, NQO2, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.351E-10 | 2.451E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.424E-09 | 6.021E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.177E-08 | 2.370E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.225E-08 | 5.171E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, NQO2, PTGS1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.044E-07 | 9.879E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.483E-07 | 5.042E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.186E-06 | 7.823E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.276E-06 | 8.174E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.543E-06 | 9.598E-04 | APP, CA12, CA2, CA7, ESR1, HIF1A, HTT, PIK3CB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.742E-32 | 1.468E-27 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.934E-06 | 1.558E-03 | CA2, CA7, HIF1A, HTT, PIK3CB, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 3.190E-06 | 1.654E-03 | PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.894E-06 | 2.317E-03 | APP, CYP1A2, CYP2C19, CYP2C9, CYP3A4, ESR1 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 6.132E-06 | 2.782E-03 | APP, CA2, CA7, ESR1, HIF1A, HTT, PIK3CB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.088E-06 | 3.150E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.558E-06 | 3.927E-03 | CA2, CA7 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.014E-05 | 7.766E-03 | CA2, CA4, CA9, SLCO1B1, SLCO1B3 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 2.098E-05 | 7.836E-03 | APP, CA2, CYP1A2, HIF1A, PTGS2, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.027E-24 | 3.296E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.983E-23 | 3.801E-19 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.026E-31 | 7.834E-29 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.831E-08 | 2.490E-06 | CYP2C9; APP; MAOA; CYP2C19; PTGS2; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.088E-07 | 4.106E-06 | PKM; PIK3CA; PIK3CB; TP53; HIF1A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.263E-07 | 4.106E-06 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.018E-07 | 6.539E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19; PTGS2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.809E-07 | 4.703E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.850E-06 | 3.436E-05 | PIK3CA; PIK3CB; TP53; ESR1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.705E-06 | 4.396E-05 | PIK3CA; PIK3CB; PTGS2; PTGS1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.078E-06 | 5.891E-05 | CYP2C9; CYP2C19; PTGS2; PTGS1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.599E-05 | 2.815E-04 | PIK3CA; PIK3CB; TP53; HIF1A; ESR1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.507E-05 | 1.781E-04 | PIK3CA; PIK3CB; PTGS2; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.025E-06 | 9.132E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.017E-04 | 8.866E-04 | PIK3CA; LMNA; PIK3CB; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 8.045E-05 | 8.045E-04 | PKM; PIK3CA; PIK3CB |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.277E-04 | 1.038E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.023E-04 | 8.866E-04 | PIK3CA; PIK3CB; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.569E-04 | 1.177E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.648E-04 | 1.177E-03 | PIK3CA; PIK3CB; PTGS2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.991E-04 | 1.177E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.730E-04 | 1.177E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.083E-04 | 1.177E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.376E-04 | 2.032E-03 | PKM; PIK3CA; PIK3CB; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.083E-04 | 1.177E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.973E-04 | 2.505E-03 | PIK3CA; PIK3CB; PTGS2; HIF1A; TP53 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.586E-04 | 1.352E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.695E-04 | 1.352E-03 | PIK3CA; PIK3CB; ESR1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.991E-04 | 1.177E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.808E-04 | 1.352E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.029E-04 | 2.254E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.901E-04 | 2.505E-03 | PIK3CA; PIK3CB; TP53 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.808E-04 | 1.352E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.864E-04 | 2.788E-03 | PIK3CA; PIK3CB; ESR1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.110E-03 | 3.900E-03 | CYP2C9; PKM; MAOA; CYP1A2; PTGS2; CYP2C19; CYP3A4; PTGS1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 7.275E-04 | 2.812E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 9.321E-04 | 3.366E-03 | PIK3CA; PIK3CB; PTGS2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 7.702E-04 | 2.861E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.198E-03 | 3.995E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.257E-03 | 4.085E-03 | PIK3CA; PIK3CB; PTGS1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.198E-03 | 3.995E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.102E-03 | 6.254E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.717E-03 | 5.314E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.611E-03 | 5.106E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.630E-03 | 7.433E-03 | PIK3CA; PIK3CB; PTGS2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 5.237E-03 | 1.362E-02 | PIK3CA; PIK3CB; TP53 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.024E-02 | 2.296E-02 | PIK3CA; PIK3CB; TP53 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.273E-02 | 2.669E-02 | PIK3CA; PIK3CB |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 6.304E-03 | 1.576E-02 | PIK3CA; PIK3CB |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.494E-02 | 2.856E-02 | PIK3CA; PTGS2; TP53 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.348E-02 | 2.738E-02 | PIK3CA; PIK3CB |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.014E-02 | 2.296E-02 | PIK3CA; PIK3CB |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.233E-03 | 1.741E-02 | PIK3CA; PIK3CB |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.273E-02 | 2.669E-02 | PIK3CA; PIK3CB |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.152E-02 | 2.538E-02 | PIK3CA; PIK3CB |
| hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 6.854E-03 | 1.681E-02 | PIK3CA; PIK3CB |
| hsa04070 | Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | 1.273E-02 | 2.669E-02 | PIK3CA; PIK3CB |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.150E-02 | 3.776E-02 | PIK3CA; PIK3CB; TP53 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 5.603E-03 | 1.428E-02 | PIK3CA; PIK3CB |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.323E-02 | 2.730E-02 | PIK3CA; PIK3CB |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.470E-03 | 1.211E-02 | PIK3CA; PIK3CB |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 8.220E-03 | 1.943E-02 | PIK3CA; PIK3CB |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.425E-02 | 2.807E-02 | PIK3CA; PIK3CB |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.477E-02 | 2.856E-02 | PIK3CA; PIK3CB |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.612E-02 | 2.994E-02 | PIK3CA; PIK3CB |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.425E-02 | 2.807E-02 | PIK3CA; PIK3CB |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.558E-02 | 2.935E-02 | PIK3CA; PIK3CB |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.809E-02 | 3.266E-02 | PIK3CA; PIK3CB |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.231E-02 | 3.868E-02 | PIK3CA; PIK3CB |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.985E-02 | 3.536E-02 | PIK3CA; PIK3CB |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.263E-02 | 3.871E-02 | PIK3CA; PIK3CB |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 2.327E-02 | 3.928E-02 | PIK3CA; PIK3CB |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.809E-02 | 3.266E-02 | PIK3CA; PIK3CB |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.623E-02 | 4.262E-02 | PIK3CA; PIK3CB |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.556E-02 | 4.206E-02 | PIK3CA; PIK3CB |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.457E-02 | 4.094E-02 | PIK3CA; PIK3CB |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.863E-02 | 4.539E-02 | PIK3CA; PIK3CB |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 2.759E-02 | 4.428E-02 | PIK3CA; PIK3CB |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.112E-02 | 4.816E-02 | PIK3CA; PIK3CB |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.625E-03 | 1.227E-02 | CYP1A2; CYP3A4 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.810E-03 | 7.771E-03 | PIK3CA; PIK3CB |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.117E-03 | 6.254E-03 | PIK3CA; PIK3CB |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.226E-03 | 6.430E-03 | MAOA; CYP1A2 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 7.355E-04 | 2.812E-03 | CA2; CA4 |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 2.935E-02 | 4.597E-02 | MAOA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 8.720E-03 | 2.024E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; ESR1; ESR1; NQO2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; PIK3CA |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; PTGS1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; SLC6A2; MAOA |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; HIF1A; TP53; PIK3CA; PIK3CB; CA1; CA9; ESR1; ESR1; NQO2; APP |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; PIK3CA; PIK3CB; CA9; PKM |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1; SLC6A2; PTGS1; PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2; MAOA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2; MAOA; MAOA |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; MAOA; APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2; MAOA; PTGS1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |